Compare McCormick & Company, Incorporated (MKC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novavax Inc — how do they compare? McCormick & Company, Incorporated trades at $53.03 (market cap $14.22B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: McCormick & Company, Incorporated is far larger — about 10.9× Novavax Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MKC | NVAX | |
|---|---|---|
Market Cap | $14.22B | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $72.26 | $11.19 |
52-Week Low | $45.60 | $6.22 |
Enterprise Value | $18.82B | $889.30M |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick (MKC) trades at $52.93, down 0.38% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion merger with Unilever's food business, expected to complete in 2027, driving positive analyst sentiment and a consensus price target of $59.67.
The outlook for MKC is positive, supported by margin expansion, strategic acquisitions, and the potential upside from the Unilever deal. Key risks include integration challenges from the merger, soft consumer volumes, and competitive pressures. With a 4% dividend yield and 35% upside to some price targets, the stock presents a compelling opportunity for long-term investors despite near-term volatility.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
